Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Pierre Fabre Médicament has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions involve 3 distinct examiners and 3 distinct art units. KAMM, JUDITH MARIE is the busiest examiner, managing 1 pending action.
The portfolio shows a one to one ratio between 3 pending office actions and 3 distinct examiners. This indicates that the company's current prosecution workload is evenly distributed across different personnel. The involvement of 3 distinct art units suggests that the active matters are spread across multiple specialized technical divisions within the biotechnology sector.
Practitioners should observe that the presence of 3 distinct examiners across 3 distinct art units minimizes the impact of any single examiner's tendencies on the overall portfolio. Because each of the 3 pending office actions is handled by a different individual, the company must manage separate prosecution tracks simultaneously. This variety in the art units suggests that the underlying technologies may span different subclasses within the broader biotechnology and pharmaceuticals fields, requiring tailored strategies for each examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KAMM, JUDITH MARIE | 1 | 42.9% | +57.1% |
| HAMA, JOANNE | 1 | 25.4% | +40.2% |
| MAHLUM, JONATHAN DAVIS | 1 | 50.0% | +23.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18909622 | EMOLLIENT COMPOSITION IN EMULSION FORM | KAMM, JUDITH MARIE | — |
| 18288634 | NEW STABLE ANTI-VISTA ANTIBODY | HAMA, JOANNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18909622 | EMOLLIENT COMPOSITION IN EMULSION FORM | KAMM, JUDITH MARIE | — |
| 18288634 | NEW STABLE ANTI-VISTA ANTIBODY | HAMA, JOANNE | — |
| 18478109 | INHIBITORS OF RAF KINASES | MAHLUM, JONATHAN DAVIS | — |
| Art Unit | Apps |
|---|---|
| 1611 | 1 |
| 1645 | 1 |
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18909622 | EMOLLIENT COMPOSITION IN EMULSION FORM | KAMM, JUDITH MARIE | 1611 | §103§112 | Non-Final OA | — | Pending | Oct 08, 2024 |
| 18288634 | NEW STABLE ANTI-VISTA ANTIBODY | HAMA, JOANNE | 1645 | §103§112DP | Non-Final OA | — | Pending | Oct 27, 2023 |
| 18478109 | INHIBITORS OF RAF KINASES | MAHLUM, JONATHAN DAVIS | 1625 | §103DP | Non-Final OA | — | Pending | Sep 29, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPierre Fabre Médicament has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Judith Marie Kamm has the most, with 1 of Pierre Fabre Médicament's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
